From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

CLICK HERE FOR CME CREDIT

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Christie M. Ballantyne, MD

Christie M. Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention

Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Chief of the Section of Cardiovascular Research
Baylor College of Medicine
Director of Atherosclerosis Laboratory
Professor of Medicine
Baylor College of Medicine